<a href="https://laohu8.com/S/TCRT">Alaunos Therapeutics</a> Inc. Completes $850,000 Private Placement of Series A-2 Convertible Preferred Stock
On June 24, 2025, Alaunos Therapeutics Inc. entered into a Subscription Agreement with various purchasers to issue and sell shares of Series A-2 Convertible Preferred Stock. A total of 850 shares were sold at a price of $1,000 per share, amounting to an aggregate purchase price of $850,000. The transaction took place in a private offering under Section 4(a)(2) of the Securities Act of 1933 and closed on the same day.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-090201), on June 26, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。